Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 14/20 | 0.60 |
| ▸ | RARA | P10276 | 11/20 | 0.60 |
| ▸ | RARG | P13631 | 11/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.34 |
| ▸ | MPL | P40238 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382145 | 0.79 | RARB (0.49) | RARBRARARARG | |
| SCHEMBL382095 | 0.75 | RARG (1.00) | RARBRARARARG | |
| SCHEMBL382094 | 0.71 | RARG (1.00) | RARBRARARARG | |
| SCHEMBL382619 | 0.71 | RARG (0.78) | RARBRARARARG | |
| SCHEMBL13196065 | 0.71 | RARG (0.80) | RARBRARARARG | |
| SCHEMBL4576213 | 0.71 | RARA (0.49) | RARBRARARARG | |
| SCHEMBL381579 | 0.70 | RARG (1.00) | RARBRARARARG | |
| SCHEMBL4576451 | 0.69 | RARG (0.69) | RARBRARARARG | |
| SCHEMBL381699 | 0.69 | RARB (0.57) | RARBRARARARG | |
| SCHEMBL382994 | 0.68 | RARA (0.51) | RARBRARARARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | RARB, RARA, RARG | RARB 1/4885RARA 2/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.